Sign In
Last checked at 
23 Jan 2015 11:44
ļ»æ
Ā
Ā
Ā
Ā
Ā
Dr. Pamela Kirby Appointment to Reckitt Benckiser Group plc
Ā
London, 23 January 2015 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) makes this announcement in accordance with Listing Rule LR 9.6.14, which requires Hikma to notify the market when directors of Hikma become directors of other publicly traded companies.
Ā
Dr. Pamela Kirby, an independent non-executive director of Hikma, has been appointed as an independent non-executive director of Reckitt Benckiser Group plc (LSE: RB) with effect from 10 February 2015.
Ā
- ENDS -
Enquiries:
Ā
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2760
Ā
Notes to EditorsĀ
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.
Ā
Ā
Ā
Follow the stocks
